Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00302822 | Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130) | PHASE3 | COMPLETED | 195 | — | — | Apr 1, 2006 | Dec 1, 2009 | Apr 7, 2026 | 1 | France |
| Arm | Type | Description |
|---|---|---|
| Intensification | EXPERIMENTAL | lopinavir or efavirenz and emtricitabine/tenofovir and intensification with enfuvirtide (week 0 to 24) |
| Standard | ACTIVE_COMPARATOR | lopinavir or efavirenz and emtricitabine/tenofovir |
| Name | Type | Description |
|---|---|---|
| enfuvirtide | DRUG | from week 0 to 24 |
| emtricitabine/tenofovir | DRUG | 1 pill/day |
| lopinavir or efavirenz | DRUG | investigator choice |
Inclusion Criteria: * Antiretroviral naïve HIV-1 infected patients * CD4 cell count below 100 per mm3, or CD4 cell count below 200/mm3 and past history or presence of B or C(AIDS defining)event * Signed informed consent Exclusion Criteria: * Pregnancy; breast feeding * Coinfection with HIV-2 or i...